co nyse qqq
slightli rais lilli fve compel mid-stag diabet
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim jul
price data oct
rate updat oct
currenc amount express
methodolog valu compani
lilli present compel phase data dual gip/
receptor agonist annual meet
european associ studi diabet
rais lilli fair valu estim
incorpor posit data well recent
approv migrain drug emgal continu
think novo oral semaglutid look well posit
strong launch believ lilli
also see strong traction inject side begin
said think demand incretin-bas
therapi continu rise time horizon
make signific chang novo nordisk
model share novo look rel fairli valu
follow declin surround releas data
sever question evolut
incretin market could affect market share
nordisk price oral semaglutid signific discount
current inject option whether payer opt prefer
gener version victoza trulic formulari
around time potenti launch
specif lilli titrat dose
need suffici control nausea
maintain efficaci still uncertainti surround
gip mechan given previou failur firm
said potenti could expand obes set
even nash long run also novo
maintain wide moat note firm exposur
increas victoza ozemp soon oral
semaglutid grow strongli rel pressur insulin
biopharmaceut busi franchis
novo total sale grow
total sale
market grow strongli sinc
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
eli lilli pharmaceut compani focu neurosci
endocrinolog oncolog immunolog lilli key product includ
alimta cancer forteo osteoporosi jardianc trulic humalog
humulin diabet ciali erectil dysfunct also lilli
hold strong posit anim pharmaceut market plan
divest late
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
launch once-weekli therapi lilli trulic novo
nordisk ozemp also benefit strong
cardiovascular outcom data novo nordisk older
inject once-daili victoza market heavili
weight toward sale market growth
remain solidli launch ozemp
year victoza sale flatten slightli lilli trulic
still launch strongli above-market growth
lilli data surpass trulic efficaci also
show potenti surpass efficaci novo
ozemp best-in-class option test
sever dose show reduct
mg dose well weight loss
kg dose trulic look weak
comparison reduct kg weight
loss arm studi refer novo sustain
trial ozemp
show lower around weight loss
kg sustain trial specif show
superior measur lilli trulic
expect novo oral semaglutid perform strongli even
lilli launch oral market could
give firm greater access primari care physician
well opportun offer slightli discount price
drug three-year lead race
market novo oral semaglutid shown slightli
lower efficaci ozemp kilogram weight loss
reduct prove superior
victoza trulic highest mg dose test
pioneer pioneer measur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqq
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
